Antibody-Functionalized Carbon Nanotube Transistors as Biosensors for the Detection of Prostate Cancer
Abstract
Prostate cancer (CaP) is the most commonly diagnosed cancer and second leading cause of cancer deaths among American men and as such represents a major public health issue. CaP displays a range of clinical behaviors, from indolent to aggressive, with development of overt metastatic disease being arguably one of most significant events in the progression of prostate cancer. At present digital rectal exams (DRE) and PSA screening are the gold-standard for detection of prostate cancer. In stark contrast to outcomes seen when diagnosed at advanced stages, detection of early-stage, localized, disease often results in successful treatment, with long-term disease-free survival in 60-90% of patients. The work associated with a this grant proposal is focused on the development of a novel biosensor platform, using validated CaP biomarkers as proof-of-concept, that we hypothesize will have increased sensitivity over currently available technologies. Such a device has the potential to improve detection, leading to better patient outcomes.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2012
- Accession Number
- ADA573827
Entities
People
- Alan T. Johnson
- Matthew T. Robinson
Organizations
- University of Pennsylvania